Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734308 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL3209613 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL6252899 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL3209615 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL4483433 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL18603363 | 0.98 | SLC6A2 (0.41) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL334961 | 0.98 | SLC6A2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL4479086 | 0.98 | SLC6A2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL335654 | 0.98 | SLC6A2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL4479090 | 0.98 | SLC6A2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-7084178-B2 | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| WO-2006041831-A2 | CYCLIC Β-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005054180-A1 | ANTIAMYLOID PHENYLSULFONAMIDES: N-CYCLOALKYLCARBOXAMIDES DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050113442-A1 | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-26 | — | — | US | disclosed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | disclosed |
| EP-1299379-A2 | LACTAM METALLOPROTEASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002004416-A2 | LACTAM METALLOPROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| US-6063615-A | Enzymatic acylation of amino acid esters using a carboxylic acid ester substituted with oxygen on the alpha carbon | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | CHRM2 4065/4885CHRM4 4558/4885CHRM3 4387/4885 |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | PREP, CTSZ, PEPD | CHRM2 4838/4885CHRM4 4825/4885CHRM3 4647/4885 |
| US-20050113442-A1 | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives | APP, PSEN1, PSEN2 | CHRM2 1452/4885CHRM4 1694/4885CHRM3 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.